|
|
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Renal Amyloidosis}}
| |
|
| |
|
| {{CMG}}; {{AE}} {{SHH}}
| |
|
| |
| ==Overview==
| |
| ==Natural History, Complications, and Prognosis==
| |
|
| |
| ===Natural History===
| |
| *The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
| |
| *The symptoms of (disease name) typically develop ___ years after exposure to ___.
| |
| *If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
| |
|
| |
| ===Complications===
| |
| *Common complications of [disease name] include:
| |
| **[Complication 1]
| |
| **[Complication 2]
| |
| **[Complication 3]
| |
|
| |
| ===Prognosis===
| |
| *Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
| |
| *Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
| |
| *The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
| |
| *[Subtype of disease/malignancy] is associated with the most favorable prognosis.
| |
| *The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
| |
|
| |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| {{WH}}
| |
| {{WS}}
| |
| [[Category: (name of the system)]]
| |